Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

High-dose chemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant Hodgkin lymphoma.

Karuturi M, Hosing C, Fanale M, Medeiros LJ, Alousi AM, de Lima MJ, Qazilbash MH, Kebriaei P, Younes A, Khouri I, Andersson BS, Champlin R, Anderlini P, Popat U.

Biol Blood Marrow Transplant. 2013 Jun;19(6):991-4. doi: 10.1016/j.bbmt.2013.03.008. Epub 2013 Mar 16.

2.

High-dose chemotherapy and autologous stem cell transplantation for relapsed or refractory nodular lymphocyte predominant Hodgkin lymphoma.

Akhtar S, Elhassan TA, Edesa W, Rauf MS, Zahir MN, Maghfoor I.

Ann Hematol. 2016 Jan;95(1):49-54.

PMID:
26467917
3.

High relapse rate in children with non-advanced nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL or nodular paragranuloma) treated with chemotherapy only.

van Grotel M, Lam KH, de Man R, Beishuizen A, Pieters R, van den Heuvel-Eibrink MM.

Leuk Lymphoma. 2006 Aug;47(8):1504-10.

PMID:
16966260
4.

A 20-year population-based study on the epidemiology, clinical features, treatment, and outcome of nodular lymphocyte predominant Hodgkin lymphoma.

Strobbe L, Valke LL, Diets IJ, van den Brand M, Aben K, Raemaekers JM, Hebeda KM, van Krieken JH.

Ann Hematol. 2016 Feb;95(3):417-23. doi: 10.1007/s00277-015-2578-6. Epub 2016 Jan 5.

5.

Double high-dose therapy with dose-intensive cyclophosphamide, etoposide, cisplatin (DICEP) followed by high-dose melphalan and autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma.

Shafey M, Duan Q, Russell J, Duggan P, Balogh A, Stewart DA.

Leuk Lymphoma. 2012 Apr;53(4):596-602. doi: 10.3109/10428194.2011.624227.

PMID:
21929284
6.

Prognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniform-modified BEAM-conditioning regimen for patients with refractory or relapsed Hodgkin lymphoma: a single-center experience.

Czyz A, Lojko-Dankowska A, Dytfeld D, Nowicki A, Gil L, Matuszak M, Kozlowska-Skrzypczak M, Kazmierczak M, Bembnista E, Komarnicki M.

Med Oncol. 2013;30(3):611. doi: 10.1007/s12032-013-0611-y. Epub 2013 May 24.

7.

Nodular lymphocyte predominant Hodgkin lymphoma behaves as a distinct clinical entity with good outcome: evidence from 14-year follow-up in the West of Scotland Cancer Network.

Farrell K, McKay P, Leach M.

Leuk Lymphoma. 2011 Oct;52(10):1920-8. doi: 10.3109/10428194.2011.584993. Epub 2011 Jun 12.

PMID:
21663507
8.

Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG).

Schulz H, Rehwald U, Morschhauser F, Elter T, Driessen C, Rüdiger T, Borchmann P, Schnell R, Diehl V, Engert A, Reiser M.

Blood. 2008 Jan 1;111(1):109-11. Epub 2007 Oct 15.

9.

Management of nodular lymphocyte predominant Hodgkin lymphoma in the modern era.

King MT, Donaldson SS, Link MP, Natkunam Y, Advani RH, Hoppe RT.

Int J Radiat Oncol Biol Phys. 2015 May 1;92(1):67-75. doi: 10.1016/j.ijrobp.2015.02.001.

PMID:
25863755
10.

Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.

Caimi PF, William BM, Silva Rondon CH, Fu P, Cooper BW, Campagnaro EL, Gerson SL, Reese-Koc J, Fox R, Creger RJ, de Lima M, Lazarus HM.

Biol Blood Marrow Transplant. 2015 Nov;21(11):1926-31. doi: 10.1016/j.bbmt.2015.06.007. Epub 2015 Jun 16.

11.

Nodular lymphocyte-predominant Hodgkin lymphoma.

Fuchs M, Eichenauer DA, Nogová L, Diehl V, Engert A; German Hodgkin Study Group..

Curr Hematol Malig Rep. 2008 Jul;3(3):126-31. doi: 10.1007/s11899-008-0019-5.

PMID:
20425457
12.

Lymphocyte-predominant Hodgkin lymphoma: what is the optimal treatment?

Fanale M.

Hematology Am Soc Hematol Educ Program. 2013;2013:406-13. doi: 10.1182/asheducation-2013.1.406. Review.

PMID:
24319212
13.

Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma.

Advani RH, Horning SJ, Hoppe RT, Daadi S, Allen J, Natkunam Y, Bartlett NL.

J Clin Oncol. 2014 Mar 20;32(9):912-8. doi: 10.1200/JCO.2013.53.2069. Epub 2014 Feb 10.

PMID:
24516013
14.

Nodular lymphocyte-predominant hodgkin lymphoma with atypical T cells: a morphologic variant mimicking peripheral T-cell lymphoma.

Sohani AR, Jaffe ES, Harris NL, Ferry JA, Pittaluga S, Hasserjian RP.

Am J Surg Pathol. 2011 Nov;35(11):1666-78. doi: 10.1097/PAS.0b013e31822832de.

PMID:
21997687
15.

Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group.

Biasoli I, Stamatoullas A, Meignin V, Delmer A, Reman O, Morschhauser F, Coiffier B, Bosly A, Diviné M, Brice P.

Cancer. 2010 Feb 1;116(3):631-9. doi: 10.1002/cncr.24819.

16.

[High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].

Avigdor A, Hardan I, Shpilberg O, Raanani P, Grotto I, Ben-Bassat I.

Harefuah. 2000 Sep;139(5-6):174-9, 248, 247. Hebrew.

PMID:
11062945
17.

Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group.

Eichenauer DA, Fuchs M, Pluetschow A, Klimm B, Halbsguth T, Böll B, von Tresckow B, Nogová L, Borchmann P, Engert A.

Blood. 2011 Oct 20;118(16):4363-5. doi: 10.1182/blood-2011-06-361055. Epub 2011 Aug 9.

18.

Chemoresistance can be overcome with high-dose chemotherapy and autologous stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.

Gerrie AS, Power MM, Shepherd JD, Savage KJ, Sehn LH, Connors JM.

Ann Oncol. 2014 Nov;25(11):2218-23. doi: 10.1093/annonc/mdu387. Epub 2014 Aug 22.

PMID:
25149708
19.

BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients.

Visani G, Malerba L, Stefani PM, Capria S, Galieni P, Gaudio F, Specchia G, Meloni G, Gherlinzoni F, Giardini C, Falcioni S, Cuberli F, Gobbi M, Sarina B, Santoro A, Ferrara F, Rocchi M, Ocio EM, Caballero MD, Isidori A.

Blood. 2011 Sep 22;118(12):3419-25. doi: 10.1182/blood-2011-04-351924. Epub 2011 Aug 3.

Supplemental Content

Support Center